NEW YORK, July 12 (GenomeWeb News) - General Electric said today that its GE Global Research unit has formed a joint research collaboration with Celera Genomics and Celera Diagnostics to discover and develop new products for personalized medicine.
Under the arrangement, GE said, the companies will work to understand and differentiate diseases at the molecular level. The first project outlined in the collaboration is designed to advance GE's efforts to develop novel imaging agents for cancer that selectively target cell surface proteins Celera Genomics has found to be associated with malignancies.
GE will have exclusive access to certain selected protein targets for research and development of imaging agents, the company said. All three companies will share certain responsibilities and costs associated with research and development, as well as value from commercial products resulting from the project, GE added.
GE, Celera Genomics, and Celera Diagnostics have also established a second project under their collaboration that focuses on the development of new algorithms and tools that advance the diagnostics and/or therapeutic programs of each company. New project agreements related to other disease areas, or tools that help create enabling technology and products may be added in the future, GE said.
Additional terms of the joint research collaboration were not disclosed.